Carrie A Schinstock

List of Publications by Year
in descending order

37 papers	1,336 citations	567281 15 h-index	377865 34 g-index
38 all docs	38 docs citations	38 times ranked	1582 citing authors

#	Article	IF	Citations
1	Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)â€“Associated Lesions: A Case Series. American Journal of Kidney Diseases, 2022, 79, 202-216.	1.9	9
2	Kidney Transplant Outcomes of Patients With Multiple Myeloma. Kidney International Reports, 2022, 7, 752-762.	0.8	7
3	Death With Function and Graft Failure After Kidney Transplantation: Risk Factors at Baseline Suggest New Approaches to Management. Transplantation Direct, 2022, 8, e1273.	1.6	9
4	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. Kidney International, 2021, 99, 707-715.	5.2	13
5	Estimating alloantibody levels in highly sensitized renal allograft candidates: Using serial dilutions to demonstrate a treatment effect in clinical trials. American Journal of Transplantation, 2021, 21, 1278-1284.	4.7	12
6	A 2020 Banff Antibodyâ€mediatedInjury Working Group examination of international practices for diagnosing antibodyâ€mediated rejection in kidney transplantation â€“ a cohort study. Transplant International, 2021, 34, 488-498.	1.6	15
7	Is the level of HLA eplet mismatch a risk factor for graft loss among kidney transplant recipients who have already formed de novo donor specific antibody?. Human Immunology, 2021, 82, 240-246.	2.4	4
8	Current Approaches to Desensitization in Solid Organ Transplantation. Frontiers in Immunology, 2021, 12, 686271.	4.8	14
9	KDOQI US Commentary on the 2020 KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. American Journal of Kidney Diseases, 2021, 77, 833-856.	1.9	7
10	Imlifidase Shows Promise for the Most Disadvantaged Sensitized Transplant Candidates. Transplantation, 2021, 105, 1660-1661.	1.0	0
11	Apples, oranges, and anything in between: In search of the best desensitization therapy. American Journal of Transplantation, 2021, 21, 3825-3826.	4.7	1
12	Antibody-Mediated Rejection: the Role of Plasma Cells and Memory B Cells. Current Transplantation Reports, 2021, 8, 272-280.	2.0	0
13	Ten Years of Kidney Paired Donation at Mayo Clinic: The Benefits of Incorporating ABO/HLA Compatible Pairs. Transplantation, 2020, 104, 1229-1238.	1.0	19
14	The need for novel trial designs, master protocols, and research consortia in transplantation. Clinical Transplantation, 2020, 34, e13759.	1.6	11
15	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group. Transplantation, 2020, 104, 911-922.	1.0	172
16	Measuring human leukocyte antigen alloantibodies: beyond a binary decision. Current Opinion in Organ Transplantation, 2020, 25, 529-535.	1.6	3
17	The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cellâ€“ and antibody-mediated rejection. American Journal of Transplantation, 2020, 20, 2318-2331.	4.7	437
18	KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. American Journal of Kidney Diseases, 2020, 75, 299-316.	1.9	38

#	Article	IF	Citations
19	Chronic Histologic Changes Are Present Regardless of HLA Mismatches. Transplantation, 2020, Publish Ahead of Print, e244-e256.	1.0	1
20	Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications. American Journal of Transplantation, 2019, 19, 123-131.	4.7	35
21	Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: Is there still a role for desensitization?. Clinical Transplantation, 2019, 33, e13751.	1.6	48
22	Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor: Implications for clinical trials. American Journal of Transplantation, 2019, 19, 2274-2283.	4.7	2
23	Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Postâ€"kidney Transplantation: A Consecutive Series of 15 Cases. Transplantation, 2019, 103, 2397-2404.	1.0	49
24	A method to reduce variability in scoring antibody-mediated rejection in renal allografts: implications for clinical trials - a retrospective study. Transplant International, 2019, 32, 173-183.	1.6	24
25	Factors at de novo donorâ€specific antibody initial detection associated with allograft loss: a multicenter study. Transplant International, 2019, 32, 502-515.	1.6	16
26	Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies. American Journal of Transplantation, 2019, 19, 1671-1683.	4.7	48
27	De novo donorâ€specific antibody following <scp>BK</scp> nephropathy: The incidence and association with antibodyâ€mediated rejection. Clinical Transplantation, 2018, 32, e13194.	1.6	35
28	Long-term Immunosuppression Adherence After Kidney Transplant and Relationship to Allograft Histology. Transplantation Direct, 2018, 4, e392.	1.6	3
29	Maintaining the Health of the Renal Allograft. Clinics in Laboratory Medicine, 2018, 38, 607-621.	1.4	0
30	32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody. Transplantation, 2017, 101, 1222-1227.	1.0	67
31	Kidney Transplant With Low Levels of DSA or Low Positive B-Flow Crossmatch. Transplantation, 2017, 101, 2429-2439.	1.0	49
32	Interpreting Anti-HLA Antibody Testing Data. Transplantation, 2016, 100, 1619-1628.	1.0	52
33	Hypertension in the Hemodialysis Patient. Advances in Experimental Medicine and Biology, 2016, 956, 327-340.	1.6	5
34	Unique Considerations When Managing Hypertension in the Transplant Patient. Advances in Experimental Medicine and Biology, 2016, 956, 341-353.	1.6	1
35	Discordance Between Iothalamate and Iohexol UrinaryÂClearances. American Journal of Kidney Diseases, 2016, 67, 49-55.	1.9	52
36	Thinking Beyond New Clinical Guidelines: Update in Hypertension. Mayo Clinic Proceedings, 2015, 90, 273-279.	3.0	5

#	Article	IF	Citations
37	Urinalysis is more specific and urinary neutrophil gelatinase-associated lipocalin is more sensitive for early detection of acute kidney injury. Nephrology Dialysis Transplantation, 2013, 28, 1175-1185.	0.7	71